Novartis will present data from 15 abstracts from its kidney portfolio at European Renal Association (ERA) Congress (CHF 119.46, 0.00)
StreetAccount Sector Summary - Healthcare Pre-Market
EMA CHMP publishes summary of opinions for May 2026 meeting
EU's CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Lupin Europe GmbH's Vislyfa
EU's CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for Novartis' Vijoice (CHF 118.94, -0.30)
Novartis to present new data at ASCO and EHA (CHF 118.54, 0.00)
White House to Announce TrumpRx Expansion With Mark Cuban - Bloomberg
Novartis presents new data from PSMAddition at AUA 2026, demonstrates improved prostate-specific antigen responses with Pluvicto combined with standard of care in PSMA-positive metastatic hormone sensitive prostate cancer (CHF 116.68, 0.00)
StreetAccount Sector Summary - China Healthcare April Recap
StreetAccount Summary - Private Company Weekly Recap - Week of 27-Apr
Powered by FactSet Research Systems Inc.